Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly “bribing” providers to prescribe its ...

Eli Lilly and Company faces valuation pressure after disappointing Orforglipron results. Discover why now isn't the time to ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly, alleging the pharmaceutical giant engaged in bribery ...

Texas Attorney General Ken Paxton has filed a lawsuit against pharmaceutical giant Eli Lilly, accusing the company of bribing medical providers to prescribe its lucrative medications. The lawsuit ...

Eli Lilly (LLY) stock in focus as Texas sues the company for alleged bribery related to weight loss drugs like Zepbound and ...

Its shares aren't exactly cheap at recent levels, though.

A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...

Weight loss drugs are big news, and Viking has one in development in both injectable and oral form. Investors are eagerly ...

The obesity market still only has two clear leaders with approved GLP-1 medications, and frontrunners Eli Lilly and Novo ...

When Eli Lilly (LLY) posted strong quarterly results, the stock fell from $750 to $625.65 by August 8. Shareholders fretted about clinical results from its next-generation obesity drug. Its 37.7% Y/Y ...

Growth investing can seem deceptively simple on the surface. In a nutshell, it involves identifying a company growing faster than the rest of the market, then betting that someone else will be ...